A Phase II, Multicenter, Single-Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Patients With Advanced Basal Cell Carcinoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Oct 2017 Results mapping the SF-36 data onto EQ-5D utilities for use in health economic evaluations, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
02 Aug 2017 Results of pooled retrospective analysis of this and other 3 studies published in the Journal of the American Academy of Dermatology.
25 May 2016 Results assessing effectiveness of the two drugs using a matching-adjusted indirect comparison from BOLT and ERIVANCE trials presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com